Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Net Cash Flow data on file, last reported at -$65.9 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 265.69% year-over-year to -$65.9 million; the trailing twelve-month figure through Dec 2025 stood at $15.9 million (down 58.7% YoY), and the FY2025 full-year result was $15.9 million, down 58.7% from the prior year.
• Net Cash Flow retreated to -$65.9 million in Q4 2025, from $88.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $88.2 million in Q3 2025 to a low of -$65.9 million in Q4 2025.
• A 5-year average of $2.3 million and a median of -$1.6 million in 2021 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 2814.45% in 2021 and soared 84636.59% in 2025, its largest moves.
• Tracing MNPR's Net Cash Flow over 5 years: stood at -$2.0 million in 2021, then plunged by 198.16% to -$6.1 million in 2022, then jumped by 128.92% to $1.8 million in 2023, then soared by 2162.54% to $39.8 million in 2024, then slumped by 265.69% to -$65.9 million in 2025.
• Business Quant data shows MNPR's Net Cash Flow at -$65.9 million in Q4 2025, $88.2 million in Q3 2025, and -$206922.0 in Q2 2025.